BCL2 and breast cancer: While Bcl2 is a favorable prognostic marker in estrogen receptor-positive BC and an independent predictor of clinical outcome in patients treated with endocrine therapy, its expression is a poor prognostic factor in TNBC patients, especially in the absence of adjuvant therapy [67].